Results 21 to 30 of about 80,637 (252)

Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma:a randomised, open-label, phase 2 trial [PDF]

, 2022
Background: Hepatocellular carcinoma has high recurrence rates after surgery; however, there are no approved standard-of-care neoadjuvant or adjuvant therapies.
Xu, Li, Yao, James C, Qayyum, Aliya, Jindal, Sonali, Mohamed, Yehia I., Allison, James Patrick, Vauthey, Jean-Nicolas, Yao, James C., Beretta, Laura, Kaseb, Ahmed Omar, Xiao, Lianchun, Chun, Yun Shin, Lee, Sunyoung S., Lee, Sunyoung S, Carter, Kristen, Yavuz, Betul Gok, Sun, Jing Jing, Basu, Sreyashi, Cristini, Vittorio, Duan, Fei, Yadav, Shalini S, Sakamuri, Divya, Sharma, Padmanee, Nicholas, Courtney, Wolff, Robert A, Vauthey, Jean Nicolas, Singh Raghav, Kanwal Pratap, Wolff, Robert A., Cao, Hop Sanderson Tran, Yadav, Shalini S., Tzeng, Ching Wei David, Sun, Ryan, Hasanov, Elshad, Rashid, Asif, Tzeng, Ching-Wei David, Mohamed, Yehia I   +35 more
core   +1 more source

Agnostic evaluation of ipilimumab and nivolumab association : a metanalysis [PDF]

, 2020
Background: Ipilimumab and Nivolumab, targeting the molecules CTLA-4, PD-1, respectively,have shown efficacy against several types of cancer. Despite these results, only a small percentage of patients maintains a long-lasting effect.
Marchetti P., Giannarelli D., Botticelli A., Ascierto A. P., Curigliano G.   +4 more
core   +3 more sources

Multi-institutional report on toxicities of concurrent nivolumab and radiation therapy

Advances in Radiation Oncology, 2018
Purpose: Radiation therapy (RT) and nivolumab are standard therapies for a wide range of advanced and metastatic cancers, yet little is known about the toxicity profile of their combined treatment.
Neha P. Amin, MD, Maliha Zainib, BS, Sean M. Parker, BS, Manuj Agarwal, MD, Malcolm D. Mattes, MD   +4 more
doaj   +1 more source

Selecting first-line immunotherapy in advanced melanoma: Current evidence on efficacy across diverse patient populations

EJC Skin Cancer
Immunotherapy has dramatically changed the outcome for patients with advanced melanoma, with significant improvements in overall survival and potential cure for some.
Sophia Kreft, Tommaso Bosetti, Rebecca Lee, Paul Lorigan   +3 more
doaj   +1 more source

Effect of Systemic Corticosteroid Therapy on the Efficacy and Safety of Nivolumab in the Treatment of Non-Small-Cell Lung Cancer

Cancer Control, 2021
Introduction: Corticosteroids are used to treat immune-related adverse events (irAEs) associated with nivolumab. However, patients with non-small-cell lung cancer who are administered corticosteroids before the initiation of nivolumab treatment are ...
Kengo Umehara, Kaori Yama, Keisuke Goto, Azusa Wakamoto, Tae Hatsuyama, Osamu Honjo, Toyohiro Saikai, Akihisa Fujita, Hideki Sato   +8 more
doaj   +1 more source

High incidence and early onset of nivolumab-induced pneumonitis: four case reports and literature review

BMC Pulmonary Medicine, 2018
Background Nivolumab, an anti-programmed cell death-1 (PD-1) monoclonal antibody used as an immune checkpoint inhibitor, is commonly employed for its anti-tumor effects against various types of malignant tumors. However, its administration is complicated
N. Koyama, O. Iwase, E. Nakashima, K. Kishida, T. Kondo, Y. Watanabe, H. Takahashi, Y. Umebayashi, Y. Ogawa, H. Miura   +9 more
doaj   +1 more source

Analyses of Nivolumab Exposure and Clinical Safety Between 3-mg/kg Dosing and 240-mg Flat Dosing in Asian Patients with Advanced Renal Cell Carcinoma in the Real-World Clinical Setting

Translational Oncology, 2020
We aimed to identify the clinical characteristics related to increased nivolumab exposure in Japanese patients with renal cell carcinoma (RCC) in real-world clinical setting.
Renpei Kato, Daiki Ikarashi, Tomohiko Matsuura, Shigekatsu Maekawa, Yoichiro Kato, Mitsugu Kanehira, Ryo Takata, Rie Tokuyama, Kanako Tamai, Naoto Harigai, Yukoh Nakazaki, Wataru Obara   +11 more
doaj   +1 more source

Cost-Effectiveness of Nivolumab Plus Cabozantinib Versus Sunitinib as a First-Line Treatment for Advanced Renal Cell Carcinoma in the United States

Frontiers in Pharmacology, 2021
Background: In a recent randomized, phase 3 trial (CheckMate 9ER), nivolumab combined with cabozantinib significantly improved patient outcomes compared with sunitinib.
SiNi Li, SiNi Li, SiNi Li, JianHe Li, LiuBao Peng, YaMin Li, YaMin Li, XiaoMin Wan   +7 more
doaj   +1 more source

Nivolumab-associated acute glomerulonephritis: Case report and literature review

, 2016
<p><strong>Background:</strong> Immune checkpoint inhibitors are changing the landscape of oncologic treatment as they are significantly improving treatment of multiple malignancies.
Xu Zeng, M.D., Ph.D., Mario Biluci, M.D., Ph.D., Kyungsuk Jung, M.D., M.P.H. (5265064), Mario Biluci, M.D., Ph.D. (5265067), Xu Zeng, M.D., Ph.D. (5265070), Kyungsuk Jung, M.D., M.P.H.   +5 more
core   +1 more source

Nivolumab-Induced Ulcerative Keratitis-A Case Report [PDF]

, 2021
Purpose: To describe a case of nivolumab-induced ulcerative keratitis rapidly recovering on topical steroid treatment and to determine changes in cytokine levels in the tear fluid caused by nivolumab.
Nuijts, R., Losonczy, G., Gijs, M., Nuijts, R.M.M.A.   +3 more
core   +2 more sources